Department of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Department of Urology, International University of Health and Welfare, Narita Hospital, 852 Hatakeda, Narita, 286-0124, Japan.
World J Surg Oncol. 2022 Jun 15;20(1):202. doi: 10.1186/s12957-022-02669-0.
Warm ischemia time (WIT) is a primary concern for robot-assisted laparoscopic partial nephrectomy (RALPN) patients because longer WIT is significantly associated with postoperative deteriorating kidney function. Tumor complexity, determined by the RENAL nephrometry score (RENAL score), can help predict surgical outcomes, but it is unclear what RENAL score and clinical factors affect WIT. This study explored the clinical factors predicting long WIT in experienced surgeon to RALPN.
In our institute, 174 RALPNs were performed between November 2013 and February 2021, of which 114 were performed by a single surgeon and included in this study. Clinical staging and the total RENAL score were determined based on preoperative CT scans. The cases were divided into three groups based on experience: period 1: 1-38, period 2: 39-76, and period 3: 77-114. The clinical factors associated with longer WIT were analyzed per period.
The overall median tumor diameter was 32 mm, and one patient had a positive surgical margin, but there were no cancer-related deaths. In total, there were 18 complications (15.8%). Periods 2 and 3 had larger tumor diameters (p < 0.01) and worse preoperative kidney function (p = 0.029) than period 1. A RENAL L-component score of 3 was associated with longer WIT in period 3 (odds ratio: 3.900; 95% confidence interval: 1.004-15.276; p = 0.044), but the tumor diameter and the total RENAL score were not.
A large tumor in the central lesion indicated by the RENAL L-component score was associated with increased WIT in RALPN.
热缺血时间 (WIT) 是机器人辅助腹腔镜部分肾切除术 (RALPN) 患者的主要关注点,因为较长的 WIT 与术后肾功能恶化显著相关。肿瘤复杂性由 RENAL 肾肿瘤评分 (RENAL 评分) 决定,可以帮助预测手术结果,但尚不清楚 RENAL 评分和临床因素如何影响 WIT。本研究探讨了经验丰富的 RALPN 外科医生预测长 WIT 的临床因素。
在我们的研究所,2013 年 11 月至 2021 年 2 月期间进行了 174 例 RALPN,其中 114 例由一名外科医生完成并包含在本研究中。临床分期和总 RENAL 评分根据术前 CT 扫描确定。根据经验将病例分为三组:第 1 期:1-38 例,第 2 期:39-76 例,第 3 期:77-114 例。按期间分析与较长 WIT 相关的临床因素。
总体中位肿瘤直径为 32mm,1 例患者切缘阳性,但无癌症相关死亡。共有 18 例并发症 (15.8%)。第 2 期和第 3 期的肿瘤直径较大 (p<0.01),术前肾功能较差 (p=0.029)。第 3 期的 RENAL L 成分评分 3 与较长的 WIT 相关 (优势比:3.900;95%置信区间:1.004-15.276;p=0.044),但肿瘤直径和总 RENAL 评分没有。
RENAL L 成分评分提示的中央病变大肿瘤与 RALPN 中 WIT 的增加有关。